Long-term exposure to sulfur dioxide (SO2), a gaseous air pollutant generated by the burning of fossil fuels, significantly increases the risk of developing amyotrophic lateral sclerosis (ALS), according to a study in Canada. Exposure to other forms of air pollution, including nitrogen dioxide (NO2), ground-level ozone (O3), and PM2.5…
News
A wearable robot that detects small arm motions and helps support the shoulder can make it easier for amyotrophic lateral sclerosis (ALS) patients to pick up and carry things, a study showed. ALS is a neurological disorder that causes progressive muscle weakness and eventual paralysis. Weak limbs make many…
Measuring the electrical activity of muscles in the neck can help clinicians to identify dysfunction in certain motor neurons — the nerve cells that control voluntary movement — in people with amyotrophic lateral sclerosis (ALS), a study from researchers in China demonstrates. Similar testing is now often done using…
Immune cells in the brain exhibit distinct profiles in the brain and spinal cord of people with amyotrophic lateral sclerosis (ALS), a study finds. A better understanding of the cells, called microglia, which are long believed to contribute to inflammation and damage in ALS, could help scientists come up…
For a rare type of amyotrophic lateral sclerosis (ALS), inhibiting a cellular stress response can normalize processes and function in specialized nerve cells called motor neurons, suggesting this response is a possible therapeutic target, a study reports. These results are specific to ALS related to the P56S mutation in…
Being exposed to rhodamine B (RhB), a toxic fluorescent dye, causes neurodegeneration and symptoms that resemble amyotrophic lateral sclerosis (ALS) in zebrafish, a study reports. The exposed zebrafish exhibited behaviors, and cellular and molecular changes similar to those in neurological disorders like ALS. Their muscles and motor abilities also…
Far-field potentials (FFPs), weak electrical signals triggered by nerve stimulation that can be recorded noninvasively on the skin, may serve as reliable clinical biomarkers to support early diagnosis and disease monitoring in people with amyotrophic lateral sclerosis (ALS), a study suggests. The strength of these signals, or FFP amplitude,…
Neuvivo and the U.S. Food and Drug Administration (FDA) have agreed on a regulatory pathway toward the potential approval of NP001 for amyotrophic lateral sclerosis (ALS), with Phase 3 clinical testing planned for 2026. The details were agreed upon in a Type C meeting and the pivotal…
In amyotrophic lateral sclerosis (ALS), the loss of any one of four RNA-binding proteins turns off a gene called UNC13A that needs to stay active for nerve cells to communicate with each other — with three of them leading to an excess of another protein, REST — pointing to…
Full randomization is nearly complete in the Phase 2/3 COMBAT-ALS trial testing MN-166 (ibudilast) for the treatment of amyotrophic lateral sclerosis (ALS), its developer, Medicinova, reported. Fewer than 10 participants remain to be assigned to a treatment group. The ongoing COMBAT-ALS trial (NCT04057898) aims to evaluate…
Recent Posts
- New funding backs commercial readiness efforts for ALS therapy
- US lawmakers reintroduce bill to improve access to treatment for ALS
- An emotional dance performance mirrored my life with ALS
- Expanded access program for ALS drug MN-166 at 50% enrollment
- US clinical trials lack diverse representation of ALS patients